Improving HPV vaccination using implementation strategies in community pharmacies: Pilot study protocol.
Journal
Research in social & administrative pharmacy : RSAP
ISSN: 1934-8150
Titre abrégé: Res Social Adm Pharm
Pays: United States
ID NLM: 101231974
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
23
05
2019
accepted:
28
05
2019
pubmed:
9
6
2019
medline:
29
7
2021
entrez:
9
6
2019
Statut:
ppublish
Résumé
Nearly 80 million people in the United States have contracted the Human Papillomavirus (HPV), and it is currently the most common sexually transmitted disease. Each year approximately 14 million people are newly infected. This study will address increasing the HPV vaccination rates by initiating a research agenda focusing on how best to utilize community pharmacies as Vaccines For Children (VFC) vaccination sites. Community pharmacies are highly accessible when compared to traditional vaccination sites due to extended evening and weekend business hours, no copays for visits, and no appointment required to speak with a pharmacist. We will conduct a Developmental Formative Evaluation using semi-structured interviews with key informants (pharmacists, pharmacy managers, technicians) from 5 Harps pharmacies to identify barriers and facilitators to community pharmacies' provision of HPV vaccine through a mixed methods design with pharmacy staff members and local physicians. We will follow that by selecting a pharmacist-physician collaborative model and identify implementation strategies through an Evidence Based Quality Improvement (EBQI) process with key stakeholders. This will be followed by piloting the selected pharmacist-physician collaborative model and implementation strategies in two Harps pharmacies (1 rural, 1 urban) on relevant implementation outcomes. This study will examine the current model of HPV vaccinations and how to improve HPV vaccination rates among adolescents by utilizing community pharmacy services.
Sections du résumé
BACKGROUND
Nearly 80 million people in the United States have contracted the Human Papillomavirus (HPV), and it is currently the most common sexually transmitted disease. Each year approximately 14 million people are newly infected.
OBJECTIVE(S)
This study will address increasing the HPV vaccination rates by initiating a research agenda focusing on how best to utilize community pharmacies as Vaccines For Children (VFC) vaccination sites. Community pharmacies are highly accessible when compared to traditional vaccination sites due to extended evening and weekend business hours, no copays for visits, and no appointment required to speak with a pharmacist.
METHODS
We will conduct a Developmental Formative Evaluation using semi-structured interviews with key informants (pharmacists, pharmacy managers, technicians) from 5 Harps pharmacies to identify barriers and facilitators to community pharmacies' provision of HPV vaccine through a mixed methods design with pharmacy staff members and local physicians. We will follow that by selecting a pharmacist-physician collaborative model and identify implementation strategies through an Evidence Based Quality Improvement (EBQI) process with key stakeholders. This will be followed by piloting the selected pharmacist-physician collaborative model and implementation strategies in two Harps pharmacies (1 rural, 1 urban) on relevant implementation outcomes.
PROJECT IMPACT
This study will examine the current model of HPV vaccinations and how to improve HPV vaccination rates among adolescents by utilizing community pharmacy services.
Identifiants
pubmed: 31174950
pii: S1551-7411(19)30555-8
doi: 10.1016/j.sapharm.2019.05.022
pmc: PMC8787867
mid: NIHMS1771587
pii:
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
336-341Subventions
Organisme : NCI NIH HHS
ID : R21 CA231180
Pays : United States
Organisme : NCATS NIH HHS
ID : U54 TR001629
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000039
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003107
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
Implement Sci. 2009 Jul 14;4:38
pubmed: 19594942
Papillomavirus Res. 2017 Jun;3:24-29
pubmed: 28720453
J Am Pharm Assoc (2003). 2010 Jan-Feb;50(1):52-61
pubmed: 20368147
J Adolesc Health. 2015 Jan;56(1):85-90
pubmed: 25438965
Pediatrics. 2013 Jun;131(6):1114-24
pubmed: 23650297
Cancer Epidemiol Biomarkers Prev. 2018 Aug;27(8):970-978
pubmed: 29871883
J Am Pharm Assoc (2003). 2013 Jan-Feb;53(1):46-53
pubmed: 23636155
Implement Sci. 2012 Mar 09;7:1-11
pubmed: 22404963
Prev Med. 2017 Jun;99:251-256
pubmed: 28188796
J Gen Intern Med. 2006 Feb;21 Suppl 2:S21-4
pubmed: 16637956
MMWR Morb Mortal Wkly Rep. 2016 Aug 26;65(33):850-8
pubmed: 27561081
Milbank Q. 2004;82(4):581-629
pubmed: 15595944
Adm Policy Ment Health. 2011 Mar;38(2):65-76
pubmed: 20957426
J Health Care Poor Underserved. 2017;28(3):973-987
pubmed: 28804072
Fam Pract. 2019 Jan 25;36(1):32-37
pubmed: 29659789
J Natl Cancer Inst. 2015 Apr 29;107(6):djv086
pubmed: 25925419
J Gen Intern Med. 2014 Dec;29 Suppl 4:904-12
pubmed: 25355087
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
J Adolesc Health. 2015 May;56(5 Suppl):S17-20
pubmed: 25863549
Am J Prev Med. 2011 Oct;41(4):428-33
pubmed: 21961471
Can Pharm J (Ott). 2014 Jan;147(1):33-44
pubmed: 24494014
Implement Sci. 2015 Aug 07;10:109
pubmed: 26249843
AIDS Care. 2011 Dec;23(12):1626-36
pubmed: 21714689
N Engl J Med. 2006 Dec 14;355(24):2523-32
pubmed: 17167135
Hum Vaccin Immunother. 2017 Aug 3;13(8):1856-1858
pubmed: 27216035
MMWR Morb Mortal Wkly Rep. 2016 Jul 08;65(26):661-6
pubmed: 27387669
J Am Pharm Assoc (2003). 2018 Sep - Oct;58(5):505-514.e2
pubmed: 30076098
Sex Transm Dis. 2013 Mar;40(3):187-93
pubmed: 23403598
Implement Sci. 2008 Mar 19;3:17
pubmed: 18353186
Pediatrics. 2012 Jun;129(6):e1437-45
pubmed: 22566415
J Gen Intern Med. 2006 Feb;21 Suppl 2:S1-8
pubmed: 16637954
MMWR Morb Mortal Wkly Rep. 2017 Jan 27;66(3):69-75
pubmed: 28125576
Prev Med. 2018 Apr;109:106-112
pubmed: 29330033
Implement Sci. 2015 Feb 12;10:21
pubmed: 25889199